Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines. / Bomholt-Riis, Jens-Kristian; Jensen, Thorbjørn Søren Rønn; Pedersen, Line; Fournais, Louise; Eskesen, Vagn; Åstrand, Ramona.

In: Danish Medical Journal, Vol. 69, No. 7, A09210697, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bomholt-Riis, J-K, Jensen, TSR, Pedersen, L, Fournais, L, Eskesen, V & Åstrand, R 2022, 'Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines', Danish Medical Journal, vol. 69, no. 7, A09210697. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-06/a09210697_web.pdf>

APA

Bomholt-Riis, J-K., Jensen, T. S. R., Pedersen, L., Fournais, L., Eskesen, V., & Åstrand, R. (2022). Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines. Danish Medical Journal, 69(7), [A09210697]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-06/a09210697_web.pdf

Vancouver

Bomholt-Riis J-K, Jensen TSR, Pedersen L, Fournais L, Eskesen V, Åstrand R. Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines. Danish Medical Journal. 2022;69(7). A09210697.

Author

Bomholt-Riis, Jens-Kristian ; Jensen, Thorbjørn Søren Rønn ; Pedersen, Line ; Fournais, Louise ; Eskesen, Vagn ; Åstrand, Ramona. / Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines. In: Danish Medical Journal. 2022 ; Vol. 69, No. 7.

Bibtex

@article{6ec2cbd779d8434e849123cce9f91585,
title = "Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines",
abstract = "INTRODUCTION: The serum biomarker S100B has been implemented in the Scandinavian Neurotrauma Committee (SNC) 2013 Head Injury Guidelines for patients classified with mild head injury (MHI). Patients with a serum S100B level less-than 0.10 μg/l sampled within six hours after trauma can be discharged without further observation or investigation. The aim of this study was to examine the influence of S100B implementation on patient costs and patient flow in an emergency department.METHODS: In this retrospective study, we included MHI patients (≥ 18 years) admitted to Rigshospitalet, Copenhagen, Denmark, between 1 February 2013 and 31 January 2014. Medical records were examined for the time of trauma, time of S100B sampling, serum S100B level, the severity of the head injury, clinical symptoms, radiological examinations, hospitalisation, discharge, surgical intervention, readmission and mortality.RESULTS: Among 2,033 patients screened for potential study candidates, 227 patients met the inclusion criteria and were enrolled in the study. Among these patients, 119 (52%) were not treated according to SNC 2013 Head Injury Guidelines, leaving 108 (48%) with full guideline adherence. Compared with MHI management without S100B, implementation of S100B produced an additional cost of €1.26 per patient. Overall, the addition of S100B did not affect the waiting time for examination with S100B sampling or CT.CONCLUSION: The use of S100B in the SNC 2013 Head Injury Guidelines did not reduce patient costs, nor did it cause substantial additional patient costs or delayed patient flow.FUNDING: none.TRIAL REGISTRATION: The Danish Data Protection Agency (journal number 2012-58-0004 and I-suite number RH-2017-164).",
keywords = "Craniocerebral Trauma/therapy, Emergency Service, Hospital, Guideline Adherence, Humans, Retrospective Studies, S100 Calcium Binding Protein beta Subunit",
author = "Jens-Kristian Bomholt-Riis and Jensen, {Thorbj{\o}rn S{\o}ren R{\o}nn} and Line Pedersen and Louise Fournais and Vagn Eskesen and Ramona {\AA}strand",
note = "Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.",
year = "2022",
language = "English",
volume = "69",
journal = "Danish Medical Journal",
issn = "2245-1919",
publisher = "Almindelige Danske Laegeforening",
number = "7",

}

RIS

TY - JOUR

T1 - Patient costs and patient flow after implementation of S100B in Scandinavian head trauma guidelines

AU - Bomholt-Riis, Jens-Kristian

AU - Jensen, Thorbjørn Søren Rønn

AU - Pedersen, Line

AU - Fournais, Louise

AU - Eskesen, Vagn

AU - Åstrand, Ramona

N1 - Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PY - 2022

Y1 - 2022

N2 - INTRODUCTION: The serum biomarker S100B has been implemented in the Scandinavian Neurotrauma Committee (SNC) 2013 Head Injury Guidelines for patients classified with mild head injury (MHI). Patients with a serum S100B level less-than 0.10 μg/l sampled within six hours after trauma can be discharged without further observation or investigation. The aim of this study was to examine the influence of S100B implementation on patient costs and patient flow in an emergency department.METHODS: In this retrospective study, we included MHI patients (≥ 18 years) admitted to Rigshospitalet, Copenhagen, Denmark, between 1 February 2013 and 31 January 2014. Medical records were examined for the time of trauma, time of S100B sampling, serum S100B level, the severity of the head injury, clinical symptoms, radiological examinations, hospitalisation, discharge, surgical intervention, readmission and mortality.RESULTS: Among 2,033 patients screened for potential study candidates, 227 patients met the inclusion criteria and were enrolled in the study. Among these patients, 119 (52%) were not treated according to SNC 2013 Head Injury Guidelines, leaving 108 (48%) with full guideline adherence. Compared with MHI management without S100B, implementation of S100B produced an additional cost of €1.26 per patient. Overall, the addition of S100B did not affect the waiting time for examination with S100B sampling or CT.CONCLUSION: The use of S100B in the SNC 2013 Head Injury Guidelines did not reduce patient costs, nor did it cause substantial additional patient costs or delayed patient flow.FUNDING: none.TRIAL REGISTRATION: The Danish Data Protection Agency (journal number 2012-58-0004 and I-suite number RH-2017-164).

AB - INTRODUCTION: The serum biomarker S100B has been implemented in the Scandinavian Neurotrauma Committee (SNC) 2013 Head Injury Guidelines for patients classified with mild head injury (MHI). Patients with a serum S100B level less-than 0.10 μg/l sampled within six hours after trauma can be discharged without further observation or investigation. The aim of this study was to examine the influence of S100B implementation on patient costs and patient flow in an emergency department.METHODS: In this retrospective study, we included MHI patients (≥ 18 years) admitted to Rigshospitalet, Copenhagen, Denmark, between 1 February 2013 and 31 January 2014. Medical records were examined for the time of trauma, time of S100B sampling, serum S100B level, the severity of the head injury, clinical symptoms, radiological examinations, hospitalisation, discharge, surgical intervention, readmission and mortality.RESULTS: Among 2,033 patients screened for potential study candidates, 227 patients met the inclusion criteria and were enrolled in the study. Among these patients, 119 (52%) were not treated according to SNC 2013 Head Injury Guidelines, leaving 108 (48%) with full guideline adherence. Compared with MHI management without S100B, implementation of S100B produced an additional cost of €1.26 per patient. Overall, the addition of S100B did not affect the waiting time for examination with S100B sampling or CT.CONCLUSION: The use of S100B in the SNC 2013 Head Injury Guidelines did not reduce patient costs, nor did it cause substantial additional patient costs or delayed patient flow.FUNDING: none.TRIAL REGISTRATION: The Danish Data Protection Agency (journal number 2012-58-0004 and I-suite number RH-2017-164).

KW - Craniocerebral Trauma/therapy

KW - Emergency Service, Hospital

KW - Guideline Adherence

KW - Humans

KW - Retrospective Studies

KW - S100 Calcium Binding Protein beta Subunit

M3 - Journal article

C2 - 35781128

VL - 69

JO - Danish Medical Journal

JF - Danish Medical Journal

SN - 2245-1919

IS - 7

M1 - A09210697

ER -

ID: 344809580